Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Liso-Cel Improved QoL vs SOC in Second-Line Treatment of Relapsed or Refractory LBCL

December 15th 2021

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

Resistance Mechanisms to BTKi in CLL

December 15th 2021

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Role of Fixed-Dose Regimens in CLL

December 15th 2021

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

Maintenance Oral Azacitidine Shows Sustained Survival Benefit in AML in First Remission

December 14th 2021

The utilization of oral azacitidine as maintenance treatment in patients with acute myeloid leukemia in first remission following intensive chemotherapy continued to showcase a survival benefit over placebo.

Magrolimab Plus Various Anti-Leukemia Therapies Being Studied for Efficacy in AML

December 14th 2021

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

Sabatolimab Demonstrates Durable Clinical Benefits in Patients With AML, High-Risk MDS

December 14th 2021

Sabatolimab, an investigational TIM-3 monoclonal antibody, induced a median duration of response greater than 1 year for patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia when used in combination with hypomethylating agents.

Link Between Elevated WBC and Thrombotic Events in Polycythemia Vera Highlights Potential Prevention Strategy

December 14th 2021

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

An Overview of Chronic Myeloid Leukemia (CML)

December 14th 2021

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.

Frontline Axi-Cel Elicits Durable Responses in High-Risk LBCL

December 14th 2021

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

Updates in AML and MPNs From ASH 2021: From Drs Srdan Verstovsek and Naval Daver

December 13th 2021

OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.

Duvelisib plus Romidepsin Displays Activity in R/R PTCL

December 13th 2021

The combination of duvelisib plus romidepsin was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma, according to final results from the dose expansion stage of a phase 1 trial.

Real-World Evidence Supports Axi-Cel in Previously Excluded LBCL Populations

December 13th 2021

Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Demonstrate Innovation in Oncology Through Extensive Hematology/Oncology Data to Be Presented at 2021 ASH Annual Meeting

December 13th 2021

Physician-scientists from Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, will present expansive new hematology/oncology data from their clinical research program at the 2021 ASH Annual Meeting and Exposition.

Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies

December 13th 2021

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.

First-Line Itolizumab Associated With High Rates of Clinical Response, Tolerability in Acute GVHD

December 13th 2021

The first-in-class monoclonal antibody treatment for acute graft-versus-host disease had durable responses and tolerability for patients.

Glofitamab Monotherapy, Plus Obinutuzumab Show High Responses in Relapsed/Refractory Follicular Lymphoma

December 13th 2021

Glofitamab, an investigational CD20xCD3 bispecific antibody, induced high response rates as monotherapy or in combination with obinutuzumab in patients with multiple relapsed or refractory follicular lymphoma.

Liso-Cel Induces Durable Responses in Relapsed/Refractory B-Cell Lymphomas

December 13th 2021

Treatment with lisocabtagene maraleucel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphomas.

Naratuximab Emtansine Plus Rituximab Serves Unmet Need in Relapsed/Refractory DLBCL Treatment

December 13th 2021

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

CHRONOS-3 in MZL: Results and Clinical Implications

December 13th 2021

Tycel Jovelle Phillips, MD, discusses recent updates from the CHRONOS-3 trial of copanlisib in R/R MZL and clinical implications of the results of this study.

Treatment Options for MZL: Second Line and Beyond

December 13th 2021

Experts in hematology/oncology discuss second-line and beyond treatment options for patients with MZL and comment on copanlisib monotherapy for the management of R/R MZL as seen in the phase 2 CHRONOS-1 study.